Effectiveness and Harms of Using Kidneys with Small Renal Tumors from Deceased or Living Donors as a Source of Renal Transplantation: A Systematic Review.


Journal

European urology focus
ISSN: 2405-4569
Titre abrégé: Eur Urol Focus
Pays: Netherlands
ID NLM: 101665661

Informations de publication

Date de publication:
05 2019
Historique:
received: 27 11 2017
revised: 03 01 2018
accepted: 25 01 2018
pubmed: 13 2 2018
medline: 10 10 2020
entrez: 14 2 2018
Statut: ppublish

Résumé

Kidney transplantation is the best treatment for patients with end-stage renal disease. Incidence of small renal masses (SRMs), which most frequently are renal cell carcinomas (RCCs), is highest in patients aged >60 yr. The increasing age of donors can lead to the diagnosis of a higher number of SRMs when assessing the patient for transplantation, and so can theoretically decrease the number of kidneys suitable for transplantation. Aiming to increase the pool of kidneys suitable for transplantation, a number of studies have reported their experience using kidneys with SRMs for transplantation. To systematically review all available evidence on the effectiveness and harm of using kidneys with SRMs as a source of transplantation. A computerized bibliographic search of the Medline, Embase, and Cochrane databases was performed for all studies reporting outcomes of adult renal transplantation using kidneys with SRMs. Nineteen studies enrolling 109 patients were included and synthesized narratively. The mean recipient age was 44.2 yr, and kidneys used were retrieved from living donors in 86% (94/109) of cases. Tumor excision was performed ex vivo in all cases except for two. The vast majority of excised tumors were RCCs (88/109 patients), and clear-cell subtype was most common. The mean tumor size was 2cm (range 0.5-6.0cm) and tumor grade was G1-G2 in 93% (75/81) of patients. With a mean follow-up of 39.9 mo, overall survival rates at 1, 3, and 5 yr were 97.7%, 95.4%, and 92%, respectively, and the mean graft survival rates 99.2%, 95%, and 95.6%, respectively. Only one local relapse occurred 9 yr after transplantation, which was managed conservatively. Functional outcomes, although infrequently reported, appear to be similar to those of conventional transplants, with 1.6% of these patients needing reoperation. The current literature, although with low-level evidence, suggests that kidneys with excised SRMs are an acceptable source of transplantation without compromising oncological outcomes and with similar functional outcomes to other donor kidneys. Renal transplantation using a kidney with a small renal mass does not appear to increase the risk of cancer recurrence and can be a good option for selected patients after appropriate counseling and allocation.

Identifiants

pubmed: 29433988
pii: S2405-4569(18)30019-1
doi: 10.1016/j.euf.2018.01.018
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

508-517

Informations de copyright

Copyright © 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Vital Hevia (V)

Urology Department, Hospital Universitario Ramón y Cajal, Alcalá University, Madrid, Spain. Electronic address: vital.hevia@salud.madrid.org.

Rhana Hassan Zakri (R)

Department of Urology and Transplant, Guy's & St Thomas' NHS Trust Hospitals, London, UK.

Claire Fraser Taylor (C)

Department of Urology and Transplant, St Georges NHS Trust Hospitals, London, UK.

Harman Maxim Bruins (HM)

Department of Urology, Radboudumc, Nijmegen, The Netherlands.

Romain Boissier (R)

Aix-Marseille University, Marseille, France; Department of Urology & Renal Transplantation, La Conception University Hospital, Assistance-Publique Marseille, France.

Enrique Lledo (E)

Department of Urology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Heinz Regele (H)

Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria.

Klemens Budde (K)

Department of Nephrology, Charité Medical University Berlin, Berlin, Germany.

Arnaldo Figueiredo (A)

Department of Urology and Renal Transplantation, Coimbra University Hospital, Coimbra, Portugal.

Alberto Breda (A)

Department of Urology, Fundacion Puigvert, University Autonoma of Barcelona, Barcelona, Spain.

Cathy Yuhong Yuan (CY)

Department of Medicine, Health Science Centre, McMaster University, Hamilton, ON, Canada.

Jonathon Olsburgh (J)

Department of Urology and Transplant, Guy's & St Thomas' NHS Trust Hospitals, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH